From: Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey
Never | Rarely | Sometimes | Routinely | p value* | ||
---|---|---|---|---|---|---|
Patient counseling | ||||||
- Diet and nutrition | EAN/EADC | 9 (8.8) | 11 (10.8) | 32 (31.4) | 49 (48) | 0.17 |
AAN | 57 (13.6) | 69 (16.4) | 132 (31.5) | 162 (38.5) | ||
- Vitamins | EAN/EADC | 16 (15.7) | 24 (23.5) | 38 (37.3) | 23 (22.5) | 0.29 |
AAN | 49 (11.6) | 84 (20.1) | 155 (36.9) | 132 (31.4) | ||
- Mental exercise | EAN/EADC | 1 (1) | 4 (3.9) | 13 (12.7) | 83 (81.4) | 0.41 |
AAN | 13 (3.0) | 21 (5.1) | 71 (17.0) | 315 (74.9) | ||
- Physical exercise | EAN/EADC | 3 (2.9) | 4 (3.9) | 13 (12.7) | 82 (80.4) | 0.78 |
AAN | 8 (1.8) | 19 (4.5) | 67 (15.9) | 327 (77.8) | ||
- Alcohol | EAN/EADC | 18 (17.6) | 14 (13.7) | 32 (31.4) | 36 (35.3) | ** |
Patient education | ||||||
- Advance planning | EAN/EADC | 1 (1) | 21 (20.6) | 42 (41.2) | 37 (36.3) | 0.08 |
AAN | 33 (7.9) | 84 (20.0) | 172 (41.0) | 130 (31) | ||
- Driving | EAN/EADC | 3 (2.9) | 16 (15.7) | 42 (41.2) | 41 (40.2) | 0.82 |
AAN | 11 (2.6) | 52 (12.3) | 186 (44.2) | 172 (40.9) | ||
- Research studies | EAN/EADC | 2 (2) | 12 (11.8) | 47 (46.1) | 40 (39.2) | < 0.0001* |
AAN | 27 (6.4) | 109 (26) | 199 (47.4) | 85 (20.2) | ||
- Support services | EAN/EADC | 0 | 17 (16.7) | 37 (36.3) | 46 (45.1) | 0.001* |
AAN | 18 (4.3) | 92 (21.9) | 195 (46.4) | 115 (27.3) | ||
- Recommendations for follow-up | EAN/EADC | 0 | 1(1) | 8 (7.8) | 91 (89.2) | 0.75 |
AAN | 0 | 5 (1.3) | 44 (10.4) | 371 (88.3) | ||
- Risk of AD and related disorder (general terms) | EAN/EADC | 1 (1) | 5 (4.9) | 25 (24.5) | 70 (68.6) | 0.55 |
AAN | 4 (1) | 37 (8.9) | 113 (27) | 265 (63) | ||
- Risk of AD and related disorders (numeric estimates) | EAN/EADC | 7 (6.9) | 24 (23.5) | 47 (46.1) | 22 (21.6) | 0.17 |
AAN | 47 (11.1) | 125 (29.8) | 150 (35.7) | 98 (23.4) | ||
- Referral to Alzheimer’s association or similar association | EAN/EADC | 15 (14.7) | 34 (33.3) | 35 (34.3) | 16 (15.7) | 0.22 |
AAN | 82 (19.5) | 153 (36.5) | 146 (34.7) | 39 (9.3) | ||
- Written summary letter of findings for patient | EAN/EADC | 9 (8.8) | 13 (12.7) | 25 (24.5) | 54 (52.9) | < 0.0001* |
AAN | 117 (27.8) | 158 (37.6) | 82 (19.6) | 63 (14.9) | ||
Medication prescribed | ||||||
- Cholinesterase inhibitors | EAN/EADC | 28 (27.5) | 16 (15.7) | 35 (4.3) | 21 (20.6) | 0.01* |
AAN | 60 (14.3) | 67 (15.9) | 189 (45) | 104 (24.8) | ||
- Memantine | EAN/EADC | 64 (62.7) | 14 (13.7) | 7 (6.9) | 13 (12.7) | 0.0001* |
AAN | 147 (35.1) | 108 (25.6) | 129 (30.7) | 36 (8.5) | ||
- Other | EAN/EADC | 26 (25.5) | 7 (6.9) | 28 (27.5) | 9 (8.8) | 0.89 |
AAN | 140 (33.3) | 45 (10.8) | 169 (40.2) | 66 (15.7) |